ECSP17040003A - Métodos para utilizar oligonucleótidos antisentido para smad7 - Google Patents
Métodos para utilizar oligonucleótidos antisentido para smad7Info
- Publication number
- ECSP17040003A ECSP17040003A ECIEPI201740003A ECPI201740003A ECSP17040003A EC SP17040003 A ECSP17040003 A EC SP17040003A EC IEPI201740003 A ECIEPI201740003 A EC IEPI201740003A EC PI201740003 A ECPI201740003 A EC PI201740003A EC SP17040003 A ECSP17040003 A EC SP17040003A
- Authority
- EC
- Ecuador
- Prior art keywords
- smad7
- methods
- sense oligonucleotides
- ibd
- oligonucleotides
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 101700026522 SMAD7 Proteins 0.000 title abstract 2
- 102000049873 Smad7 Human genes 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen métodos para tratar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD utilizando oligonucleótidos antisentido para SMAD7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462097012P | 2014-12-26 | 2014-12-26 | |
US201562235269P | 2015-09-30 | 2015-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP17040003A true ECSP17040003A (es) | 2017-10-31 |
Family
ID=56151259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201740003A ECSP17040003A (es) | 2014-12-26 | 2017-06-23 | Métodos para utilizar oligonucleótidos antisentido para smad7 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20190112608A1 (es) |
EP (1) | EP3237018A4 (es) |
JP (1) | JP2018502107A (es) |
KR (1) | KR20170105529A (es) |
CN (1) | CN107405413A (es) |
AU (1) | AU2015371325A1 (es) |
BR (1) | BR112017013765A2 (es) |
CA (1) | CA2971583A1 (es) |
CL (1) | CL2017001701A1 (es) |
CO (1) | CO2017007383A2 (es) |
EA (1) | EA201791471A1 (es) |
EC (1) | ECSP17040003A (es) |
IL (1) | IL253023A0 (es) |
MA (1) | MA41271A (es) |
MX (1) | MX2017008462A (es) |
SG (1) | SG11201705179TA (es) |
WO (1) | WO2016105516A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015332624A1 (en) | 2014-10-17 | 2017-05-04 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
WO2018111323A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease |
EP3799604A4 (en) * | 2018-05-09 | 2022-09-07 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2399550A1 (en) * | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
CA2486147A1 (en) * | 2002-05-17 | 2003-11-27 | Protein Design Labs, Inc. | Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
CA2662535A1 (en) * | 2006-09-08 | 2008-03-13 | Ore Pharmaceuticals Inc. | Method for reducing or alleviating inflammation in the digestive tract |
DK2099446T3 (da) * | 2006-11-17 | 2013-02-11 | Shire Dev Inc | Fremgangsmåde til behandling af inflammatorisk tarmsygdom |
JP2012500242A (ja) * | 2008-08-18 | 2012-01-05 | グラクソ グループ リミテッド | Il−18アンタゴニストを用いる自己免疫疾患の治療 |
CA2743329C (en) * | 2008-11-13 | 2020-09-01 | Giuliani International Limited | Antisense compositions and methods of making and using same |
TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
CN104040349B (zh) * | 2011-09-15 | 2017-07-04 | 诺格尔制药有限公司 | 用于监测对抗smad7疗法的反应性的方法 |
MX2016014624A (es) * | 2014-05-09 | 2017-05-25 | Nogra Pharma Ltd | Metodos para el tratamiento de enfermedad inflamatoria del intestino. |
WO2015011694A2 (en) * | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues of smad7 antisense oligonucleotides |
US20170233736A1 (en) * | 2014-10-17 | 2017-08-17 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
-
2015
- 2015-12-22 MA MA041271A patent/MA41271A/fr unknown
- 2015-12-23 MX MX2017008462A patent/MX2017008462A/es unknown
- 2015-12-23 AU AU2015371325A patent/AU2015371325A1/en not_active Abandoned
- 2015-12-23 CA CA2971583A patent/CA2971583A1/en not_active Abandoned
- 2015-12-23 CN CN201580076967.0A patent/CN107405413A/zh active Pending
- 2015-12-23 WO PCT/US2015/000269 patent/WO2016105516A1/en active Application Filing
- 2015-12-23 KR KR1020177020587A patent/KR20170105529A/ko unknown
- 2015-12-23 BR BR112017013765A patent/BR112017013765A2/pt not_active IP Right Cessation
- 2015-12-23 EP EP15873796.5A patent/EP3237018A4/en not_active Ceased
- 2015-12-23 EA EA201791471A patent/EA201791471A1/ru unknown
- 2015-12-23 JP JP2017534594A patent/JP2018502107A/ja active Pending
- 2015-12-23 US US15/539,497 patent/US20190112608A1/en not_active Abandoned
- 2015-12-23 SG SG11201705179TA patent/SG11201705179TA/en unknown
-
2017
- 2017-06-19 IL IL253023A patent/IL253023A0/en unknown
- 2017-06-23 CL CL2017001701A patent/CL2017001701A1/es unknown
- 2017-06-23 EC ECIEPI201740003A patent/ECSP17040003A/es unknown
- 2017-07-25 CO CONC2017/0007383A patent/CO2017007383A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018502107A (ja) | 2018-01-25 |
CN107405413A (zh) | 2017-11-28 |
EP3237018A1 (en) | 2017-11-01 |
MX2017008462A (es) | 2018-02-26 |
MA41271A (fr) | 2017-10-31 |
IL253023A0 (en) | 2017-08-31 |
WO2016105516A1 (en) | 2016-06-30 |
US20190112608A1 (en) | 2019-04-18 |
WO2016105516A8 (en) | 2017-07-06 |
EP3237018A4 (en) | 2018-07-11 |
AU2015371325A1 (en) | 2017-07-13 |
CO2017007383A2 (es) | 2018-01-05 |
BR112017013765A2 (pt) | 2018-02-27 |
EA201791471A1 (ru) | 2017-12-29 |
CL2017001701A1 (es) | 2018-04-06 |
CA2971583A1 (en) | 2016-06-30 |
KR20170105529A (ko) | 2017-09-19 |
SG11201705179TA (en) | 2017-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17040003A (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
IL284423A (en) | Antisense oligonucleotides for the treatment of Pompe disease | |
LT3386511T (lt) | Hantingtono ligos gydymo būdai | |
HK1232141A1 (zh) | 用於治療亨廷頓病的方法和組合物 | |
CO2017004314A2 (es) | Compuestos anti-tnf | |
IL276516A (en) | Methods for diagnosing and treating inflammatory bowel disease | |
BR112016016792A2 (pt) | Aparelho para tratamento de vestuário | |
HK1231401A1 (zh) | 治療阿爾茨海默氏病的方法 | |
WO2017055611A3 (en) | Methods of using smad7 antisense oligonucleotides based on biomarker expression | |
IL278247B (en) | mct4 inhibitors to treat the disease | |
HK1253238A1 (zh) | 用於治療疾病的gls1抑制劑 | |
BR112016029363A2 (pt) | método para manufaturar frauda descartável do tipo roupa íntima e frauda descartável do tipo roupa íntima | |
BR112016020381A2 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
DK3167078T3 (da) | HCBI-, MSBI-, MSSI- og CMI-sekvenser til en tidlig markør for fremtidig udvikling af cancer og sygdomme i CNS og som et target for behandling og forebyggelse af disse sygdomme | |
PT3164394T (pt) | Inibidores gls1 para o tratamento de doenças | |
CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
CO2017010530A2 (es) | Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos | |
DK3119886T3 (da) | Kopiantalsbevarende RNA-analysefremgangsmåde | |
BR112016029236A2 (pt) | métodos para tratar prurido. | |
IL252904A0 (en) | Methods and factors for treating diseases | |
BR112016015712A8 (pt) | método de tratamento de doenças hepáticas. | |
GB201410407D0 (en) | Treatment of chagas disease | |
TH1501005286A (th) | การทำไบโอเจเนซิสของ mirna ในเอ็กโซโซมสำหรับการวินิจฉัยและการรักษาโรค | |
ES1149211Y (es) | Sonda Exofágica de Extracción para ganado |